- Home
- HOV vs XNCR Comparison
HOV vs XNCR Comparison
Compare HOV & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOV
- XNCR
- Stock Information
- Founded
- HOV 1959
- XNCR 1997
- Country
- HOV United States
- XNCR United States
- Employees
- HOV N/A
- XNCR N/A
- Industry
- HOV Homebuilding
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- HOV Consumer Discretionary
- XNCR Health Care
- Exchange
- HOV Nasdaq
- XNCR Nasdaq
- Market Cap
- HOV 705.4M
- XNCR 565.1M
- IPO Year
- HOV N/A
- XNCR 2013
- Fundamental
- Price
- HOV $133.18
- XNCR $7.23
- Analyst Decision
- HOV Sell
- XNCR Buy
- Analyst Count
- HOV 2
- XNCR 8
- Target Price
- HOV $120.00
- XNCR $26.43
- AVG Volume (30 Days)
- HOV 125.9K
- XNCR 623.7K
- Earning Date
- HOV 08-21-2025
- XNCR 08-06-2025
- Dividend Yield
- HOV N/A
- XNCR N/A
- EPS Growth
- HOV N/A
- XNCR N/A
- EPS
- HOV 28.18
- XNCR N/A
- Revenue
- HOV $3,062,436,000.00
- XNCR $146,929,000.00
- Revenue This Year
- HOV $0.00
- XNCR N/A
- Revenue Next Year
- HOV $2.50
- XNCR $28.84
- P/E Ratio
- HOV $4.69
- XNCR N/A
- Revenue Growth
- HOV 7.85
- XNCR N/A
- 52 Week Low
- HOV $81.15
- XNCR $7.07
- 52 Week High
- HOV $240.34
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- HOV 65.84
- XNCR 29.99
- Support Level
- HOV $117.95
- XNCR $7.07
- Resistance Level
- HOV $136.49
- XNCR $8.21
- Average True Range (ATR)
- HOV 6.31
- XNCR 0.54
- MACD
- HOV 0.93
- XNCR -0.20
- Stochastic Oscillator
- HOV 82.63
- XNCR 5.35
About HOV Hovnanian Enterprises Inc.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.